Conference Presentation Schedules, Executive Appointments, and Product Availability - Research Report on Mallinckrodt,

    Conference Presentation Schedules, Executive Appointments, and Product
 Availability - Research Report on Mallinckrodt, Haemonetics, Select Medical,
                        Horizon Pharma, and ImmunoGen

Editor Note: For more information about this release, please scroll to bottom

PR Newswire

NEW YORK, January 7, 2014

NEW YORK, January 7, 2014 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting
Mallinckrodt plc (NYSE: MNK), Haemonetics Corporation (NYSE: HAE), Select
Medical Holdings Corporation (NYSE: SEM), Horizon Pharma, Inc. (NASDAQ: HZNP),
and ImmunoGen, Inc. (NASDAQ: IMGN). Today's readers may access these reports
free of charge - including full price targets, industry analysis and analyst
ratings - via the links below.

Mallinckrodt plc Research Report

On January 2, 2014, Mallinckrodt plc (Mallinckrodt) announced its
participation at the 32^nd Annual J.P. Morgan Healthcare Conference in San
Francisco. The Company informed that Mallinckrodt's President and CEO, Mark
Trudeau, is scheduled to make the presentation on January 15, 2014 at 2:30
p.m. PST / 5:30 p.m. EST. The Full Research Report on Mallinckrodt plc -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/24f6_MNK

--

Haemonetics Corporation Research Report

On January 2, 2014, Haemonetics Corporation (Haemonetics) announced that it
will participate at the 32^nd Annual J.P. Morgan Health Conference in San
Francisco. The Company stated that Haemonetics' President and CEO, Brian
Concannon, is scheduled to make a presentation on January 15, 2014 at 10:00
a.m. PT / 1:00 p.m. ET. According to the Company, interested parties can
access a live webcast of Mr. Concannon's presentation via a link given in the
website of the Company. The Full Research Report on Haemonetics Corporation -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/7c61_HAE

--

Select Medical Holdings Corporation Research Report

On December 23, 2013, Select Medical Holdings Corporation (Select Medical)
announced that its Board of Directors has appointed David S. Chernow as the
President and CEO of the Company, effective from January 1, 2014. The Company
notified that Chernow has served as the Company's President since September
2010. Additionally, the Board reported the appointments of Robert A. Ortenzio
to serve as the Company's Executive Chairman and Co-Founder, as well as that
of Rocco A. Ortenzio as the Company's Vice Chairman and Co-Founder, effective
from January 1, 2014. The Full Research Report on Select Medical Holdings
Corporation - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/8287_SEM

--

Horizon Pharma, Inc. Research Report 

On January 2, 2014, Horizon Pharma, Inc. (Horizon Pharma) announced the
availability of Horizon-labeled VIMOVO (naproxen/esomeprazole magnesium)
tablets in US, for the relief of signs and symptoms of osteoarthritis (OA),
rheumatoid arthritis (RA) and ankylosing spondylitis and to decrease the risk
of stomach (gastric) ulcers in patients at risk of developing stomach ulcers
from treatment with non-steroidal anti-inflammatory drug (NSAIDs). The Company
informed that it expects to launch Horizon-labeled VIMOVO commercially with
its primary care sales force on February 3, 2014. "The availability of
Horizon-labeled VIMOVO is a major milestone for us as we plan for our full
commercial launch. We expect to complete hiring and training our expanded
sales force this month and commence our launch of VIMOVO in early February,"
said Timothy P. Walbert, Chairman, President, and CEO of Horizon Pharma.
"Effective today, VIMOVO is now available via our co-pay program and is also
included in our Prescriptions-Made-Easy specialty pharmacy program, ensuring
VIMOVO is available at a reasonable out-of-pocket cost to patients." The Full
Research Report on Horizon Pharma, Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at:

http://www.analystscorner.com/r/full_research_report/05ea_HZNP

--

ImmunoGen, Inc. Research Report

On December 30, 2013, ImmunoGen, Inc. (ImmunoGen) announced the appointment of
David Johnston as the Company's Executive Vice President and CFO, with
immediate effect. The Company stated that in his new role, David will report
to Daniel Junius, President and CEO of ImmunoGen. Prior to joining the
Company, Johnston served as CFO at AVEO Pharmaceuticals, Inc. "I am delighted
to have Dave join ImmunoGen," said Mr. Junius. "His depth of experience in
both senior financial positions and in corporate planning makes Dave
well-suited to help successfully advance the Company to our next stages." The
Full Research Report on ImmunoGen, Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at:

http://www.analystscorner.com/r/full_research_report/11c8_IMGN

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Nidhi Vatsal, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

SOURCE Analysts' Corner

Contact: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North America)
 
Press spacebar to pause and continue. Press esc to stop.